

Integrated platform for hit identification and optimization: computational and biophysical assets

Prof. Bottegoni - Dr. Elisi - Dr. Vanzolini

MISSIONE 4
ISTRUZIONE
RICERCA



Finanziato
dall'Unione europea
NextGenerationEU



Ministero
dell'Università
e della Ricerca




Italiadomani
PIANO NAZIONALE
DI RIPRESA E RESILIENZA



1506
UNIVERSITÀ
DEGLI STUDI
DI URBINO
CARLO BO

WP1 - Development of a third party-accessible, enabling platform for efficient preclinical drug discovery



- Ultra Large Commercial Libraries (10^9)
- DL-generated Compounds (10^7)
- Combinatorial SAR Explorations (10^4)

Compound Prioritization by
Computational Means
(10^2)



Biochemical
or Functional
Assays



Surface
Plasmon
Resonance
(SPR)



MicroScale
Thermophoresis
(MST)



Circular
Dichroism
(CD)



Biophysical Assays

Nuclear
Magnetic
Resonance
(NMR)



HPC platform for virtual screening campaign

TASK1.1 - Setting Up and Validating a Hit Identification Computational Facility as part of VITALITY Enabling Platform for Drug Discovery





HPC infrastructure is currently being installed @Campus Enrico Mattei (P74 01.01.01.74)

- ☐ 2 AMD Epyc 64-Core 7713 2.00 GHz 256 MB
- ☐ 4 GPU NVIDIA RTX A6000 48 GB
- ☐ Increased storage capacity to nearly 40 TB with a shared repository:
 - ☐ Prepared libraries, including diversity sets, covalent inhibitors and biomimetics, in a readable format for docking calculations
 - ☐ Enamine REAL (2022q34) as binary 1D-fingerprints allowing for screening of commercial compounds (purchased December 2023)
 - ☐ Upcoming preparation of Python scripts allowing for:
 - ☐ batch interrogation of online databases (i.e., ChEMBL, SwissTargetPrediction, PolyPharmacologyBrowser2, etc.)
 - ☐ pipeline allowing for active learning docking to prioritize compounds for virtual screening
 - ☐ customized protocols for molecular dynamics workflows as fast virtual screening post-processing tools





HPC platform for virtual screening campaign

Software capabilities


- | | | |
|---|---|---|
| <ul style="list-style-type: none"><input type="checkbox"/> Virtual screening<ul style="list-style-type: none"><input type="checkbox"/> Structure-based: Glide<input type="checkbox"/> Ligand-based: Shape, Phase |  | Hit identification and validation
Lead optimization |
| <ul style="list-style-type: none"><input type="checkbox"/> Molecular dynamics/enhanced sampling simulations<ul style="list-style-type: none"><input type="checkbox"/> Desmond, Amber, Gromacs<input type="checkbox"/> BiKiLifeSciences<input type="checkbox"/> Plumed |  | Hit prioritization
Lead optimization
Mechanistic studies |
| <ul style="list-style-type: none"><input type="checkbox"/> QM / QM-MM calculations<ul style="list-style-type: none"><input type="checkbox"/> Amber, Jaguar |  | Lead optimization
Mechanistic studies
Support to synthetic organic chemistry |
| <ul style="list-style-type: none"><input type="checkbox"/> Data processing<ul style="list-style-type: none"><input type="checkbox"/> DataWarrior, Knime<input type="checkbox"/> RDKit, Python libraries |  | Data analysis
Machine learning applications
Lead optimization |

HPC platform for virtual screening campaign

Case study: Selection of potential adenosine 5'-phosphosulfate reductase potential inhibitors



6.5 B commercial compounds



MM-GBSA score (kcal/mol)	log_RTcalc_min
-42.35	-1.53
-36.27	-2.09
-43.44	-2.14
-44.59	-2.34
-44.66	-3.09
-49.22	-3.12
-43.04	-3.26
-43.59	-3.30
-40.17	-3.42
-45.76	-3.45
-46.82	-3.47
-39.46	-3.65
-55.13	-4.08
-35.61	-4.48
-39.4	-4.76
-30.27	-3.20
-41.35	-4.80
-45.27	-2.27
-40.24	-3.35
-48.53	-3.62
-38.01	-3.86
-30.24	-4.65
-43.54	-5.68
-35.46	-4.84


Surface Plasmon Resonance



Cytiva Biacore™ 1K


How strong?

Affinity reflects the binding strength




How fast?

Kinetics determine how fast/slow a complex forms or dissociates




How much?

Qualitative and quantitative determination of active analyte **concentration**




How specific?

Is the molecule **specific** for its target?






How similar?


Comparable to reference product or not?



Dia-T51



C. albicans



N. Gow et al. 2017

Cycle	Flow cell	Sensorgram type	Analysis step purpose	Single cycle kinetics 1 Solution	Single cycle kinetics 1 Concentrations (nM)	SCK binding late_1_6 Relative (RU)	Capture level_2 Relative (RU)
7	2-1	Reference subtracted	Analysis	Laminarin	0.69 2.06 6.17 18.52 55.57 166 [nM]	112.9	2592.0

Group	General Kinetics model	Curve markers	Flow cell	Injection variables Capture 1 Solution	Single cycle kinetics 1 Solution	Quality Kinetics Chi² (RU²)	1:1 binding ka (1/Ms)	kd (1/s)	KD (M)	Rmax (RU)	tc
1	1:1 binding		2-1	Irrilevant mAb	Laminarin	3.29e+00	1.87e+05	6.71e-04	3.59e-09	79.7	1.02e+12